

MPSV4

Vaccine	Age	Administration	Recommendation	Booster
MPSV4 (Menomune) <i>Sanofi Pasteur</i>	2 years and older & ≥56 years	0.5 mL subcutaneously (SC)	Not routinely recommended.	No

Meningococcal Polysaccharide Vaccine Recommendations

- Routine vaccination with MPSV4 is not recommended.
- Use should be limited to persons older than 55 years or when neither meningococcal conjugate (MenACWY) vaccine is available.
- Preferred for meningococcal vaccine-naïve persons aged ≥56 years who anticipate requiring a single dose of meningococcal vaccine (e.g. travelers and persons at risk as a result of a community outbreak).
- Preferred for persons aged ≥65 years who were vaccinated previously with MenACWY and are recommended for revaccination or for whom multiple doses are anticipated (e.g. persons with asplenia and microbiologists).

Recommendation for Persons Aged 2 Through 54 Years Who Receive MPSV4:

- Children who received primary immunization with MPSV4 before 7 years of age and remain at increased risk for meningococcal disease should receive a booster 3 years after primary immunization.
 - ❖ Boosters should be repeated every 5 years thereafter.
- Children who received primary immunization with MPSV4 at 7 years of age or older and remain at increased risk for meningococcal disease should receive a booster 5 years after their previous dose.
 - ❖ Boosters should be repeated every 5 years thereafter.



Contraindications

- Contraindicated in persons known to have had a severe allergic reaction (anaphylaxis) to a vaccine component, including diphtheria or tetanus toxoid.

Precautions

- Moderate or severe acute illness.

Adverse Reactions

- Fever (100°F - 103°F) within 7 days of vaccination.
- Headache, malaise within 7 days of vaccination
- Pain and redness at the injection site.

IP-B71-VMPSV-V1 (05/05/16)